These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2272767)

  • 1. Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing schedule.
    Budman DR; Kreis W; Behr J; Schulman P; Lichtman S; Allen SL; Weiselberg L; Satterlee WG; Nelson RL; Vinciguerra V
    Invest New Drugs; 1990 Aug; 8(3):269-74. PubMed ID: 2272767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of vinzolidine.
    Budman DR; Schulman P; Marks M; Vinciguerra V; Weiselberg L; Kreis W; Degnan TJ
    Cancer Treat Rep; 1984; 68(7-8):979-82. PubMed ID: 6744350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors.
    Takasugi BJ; Robertone AB; Salmon SE; Jones SE; Alberts DS
    Invest New Drugs; 1984; 2(4):387-90. PubMed ID: 6096287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacokinetic study of intravenous vinzolidine.
    Taylor CW; Salmon SE; Satterlee WG; Robertone AB; McCloskey TM; Holdsworth MT; Plezia PM; Alberts DS
    Invest New Drugs; 1990; 8 Suppl 1():S51-7. PubMed ID: 2380017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of a new vinca alkaloid derivative, S12363, in advanced breast cancer.
    Adenis A; Pion JM; Fumoleau P; Pouillart P; Marty M; Giroux B; Bonneterre J
    Cancer Chemother Pharmacol; 1995; 35(6):527-8. PubMed ID: 7882462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum.
    Sarna G; Mitsuyasu R; Figlin R; Ambersley J; Groopman J
    Cancer Chemother Pharmacol; 1985; 14(1):12-4. PubMed ID: 3965155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
    Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
    Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of intravenously injected tritiated vinzolidine.
    Kreis W; Budman DR; Freeman J; Bergstrom RF; Nelson RL
    Cancer Chemother Pharmacol; 1990; 26(6):419-22. PubMed ID: 2225313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
    Drengler RL; Kuhn JG; Schaaf LJ; Rodriguez GI; Villalona-Calero MA; Hammond LA; Stephenson JA; Hodges S; Kraynak MA; Staton BA; Elfring GL; Locker PK; Miller LL; Von Hoff DD; Rothenberg ML
    J Clin Oncol; 1999 Feb; 17(2):685-96. PubMed ID: 10080615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
    Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
    Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
    Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
    Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
    Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
    J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of Taxotere: five-day schedule.
    Pazdur R; Newman RA; Newman BM; Fuentes A; Benvenuto J; Bready B; Moore D; Jaiyesimi I; Vreeland F; Bayssas MM
    J Natl Cancer Inst; 1992 Dec; 84(23):1781-8. PubMed ID: 1359154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.
    Negoro S; Fukuoka M; Masuda N; Takada M; Kusunoki Y; Matsui K; Takifuji N; Kudoh S; Niitani H; Taguchi T
    J Natl Cancer Inst; 1991 Aug; 83(16):1164-8. PubMed ID: 1653362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma.
    Hutson TE; Ganapathi R; Elson P; Mekhail T; Olencki T; Budd GT; Bukowski RM
    Invest New Drugs; 2004 Aug; 22(3):277-84. PubMed ID: 15122074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
    Rowinsky EK; Noe DA; Grochow LB; Sartorious SE; Bowling MK; Chen TL; Lubejko BG; Kaufmann SH; Donehower RC
    J Clin Oncol; 1995 Aug; 13(8):1975-84. PubMed ID: 7636538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
    Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.